[go: up one dir, main page]

MX2022010040A - Compuestos moduladores de gcn2. - Google Patents

Compuestos moduladores de gcn2.

Info

Publication number
MX2022010040A
MX2022010040A MX2022010040A MX2022010040A MX2022010040A MX 2022010040 A MX2022010040 A MX 2022010040A MX 2022010040 A MX2022010040 A MX 2022010040A MX 2022010040 A MX2022010040 A MX 2022010040A MX 2022010040 A MX2022010040 A MX 2022010040A
Authority
MX
Mexico
Prior art keywords
gcn2
modulating compounds
formula
compounds
modulating
Prior art date
Application number
MX2022010040A
Other languages
English (en)
Inventor
Balaji Dashrath Sathe
Sebastian Bernales
Brahmam Pujala
Díaz Gonzalo Andrés Ureta
Jennifer Borthwick
Original Assignee
Alesta Therapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2002144.0A external-priority patent/GB202002144D0/en
Priority claimed from GBGB2007163.5A external-priority patent/GB202007163D0/en
Application filed by Alesta Therapeutics BV filed Critical Alesta Therapeutics BV
Publication of MX2022010040A publication Critical patent/MX2022010040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Secondary Cells (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las descripciones del presente documento se refieren a nuevos compuestos de la Fórmula (1): (ver Fórmula) (1); o una de sus sales, en donde X, Y, R1, R2, R3, R4 y R5 se definen aquí, y a su uso para tratar, prevenir, mejorar, controlar o reducir el riesgo de trastornos asociados con el Control General No depresible 2 (GCN2).
MX2022010040A 2020-02-17 2021-02-17 Compuestos moduladores de gcn2. MX2022010040A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002144.0A GB202002144D0 (en) 2020-02-17 2020-02-17 Pharmaceutical compounds
GBGB2007163.5A GB202007163D0 (en) 2020-05-14 2020-05-14 Pharmaceutical compounds
PCT/EP2021/053928 WO2021165346A1 (en) 2020-02-17 2021-02-17 Gcn2 modulator compounds

Publications (1)

Publication Number Publication Date
MX2022010040A true MX2022010040A (es) 2022-09-05

Family

ID=74672306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010040A MX2022010040A (es) 2020-02-17 2021-02-17 Compuestos moduladores de gcn2.

Country Status (11)

Country Link
US (1) US20230143059A1 (es)
EP (1) EP4107146A1 (es)
JP (1) JP2023514328A (es)
KR (1) KR20220143717A (es)
CN (1) CN115768750B (es)
AU (1) AU2021222818A1 (es)
BR (1) BR112022016072A2 (es)
CA (1) CA3170652A1 (es)
IL (1) IL295487A (es)
MX (1) MX2022010040A (es)
WO (1) WO2021165346A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
WO2021262596A1 (en) 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
AU2021381949A1 (en) 2020-11-18 2023-06-15 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
JP2024504364A (ja) * 2021-01-22 2024-01-31 ヒベルセル， インコーポレイテッド Ｇｃｎ２をモジュレートする化合物およびその使用
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
JP2024544632A (ja) * 2021-12-03 2024-12-03 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物
WO2023159322A1 (en) * 2022-02-25 2023-08-31 Ontario Institute For Cancer Research (Oicr) Quinazoline derivatives as inhibitors of the gcn2 kinase, compositions and uses thereof
EP4504720A1 (en) * 2022-04-08 2025-02-12 Alesta Therapeutics BV Gcn2 modulator compounds
CA3252213A1 (en) 2022-05-11 2023-11-16 Ip2Ipo Innovations Limited GCN2 INHIBITOR
EP4491626A4 (en) * 2022-06-08 2025-07-09 Korea Res Inst Chemical Tech PHENYLSULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THEM AS ACTIVE INGREDIENT
KR102843093B1 (ko) * 2022-06-08 2025-08-06 주식회사 애스톤사이언스 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN115073282A (zh) * 2022-06-08 2022-09-20 都创(重庆)医药科技有限公司 一种基于微通道连续流技术快速制备3-溴-2,4-二氟苯甲酸的方法
WO2025043350A1 (en) * 2023-08-30 2025-03-06 Ontario Institute For Cancer Research (Oicr) Triazolopyridopyrimidine and dihydroimidazopyridopyrimidine derivatives as inhibitors of the gcn2 kinase, compositions and uses thereof
WO2025043349A1 (en) * 2023-08-30 2025-03-06 Ontario Institute For Cancer Research (Oicr) Pyrimidopyridone and pteridone derivatives as inhibitors of the gcn2 kinase, compositions and uses thereof
WO2025076441A1 (en) * 2023-10-06 2025-04-10 Alesta Therapeutics BV Compounds of gcn2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
BR112014029404A2 (pt) * 2012-05-31 2017-06-27 Hoffmann La Roche compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção
JP6374384B2 (ja) * 2012-08-07 2018-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
RU2753520C2 (ru) * 2016-06-21 2021-08-17 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы
MA45940B1 (fr) * 2016-08-10 2024-12-31 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP3630748B1 (en) * 2017-06-01 2023-04-19 Cornell University Ire1 small molecule inhibitors
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions

Also Published As

Publication number Publication date
CN115768750A (zh) 2023-03-07
IL295487A (en) 2022-10-01
JP2023514328A (ja) 2023-04-05
KR20220143717A (ko) 2022-10-25
WO2021165346A1 (en) 2021-08-26
BR112022016072A2 (pt) 2022-10-04
EP4107146A1 (en) 2022-12-28
CN115768750B (zh) 2025-09-23
CA3170652A1 (en) 2021-08-26
US20230143059A1 (en) 2023-05-11
AU2021222818A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MX2022010040A (es) Compuestos moduladores de gcn2.
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CO2020014586A2 (es) Compuestos
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2022011333A (es) Compuestos moduladores de gpr52.
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
BR112021023895A2 (pt) Compostos herbicidas
UY37647A (es) Amidas de ácido n–(1,3,4–oxadiazol–2–il)arilcarboxílico sustituidas y su compuesto como herbicidas
CO2022010431A2 (es) Nuevo derivado de pirazol
CL2021000903A1 (es) Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
CL2020000376A1 (es) Compuesto pentacíclico.
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2019000103A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CL2024000742A1 (es) Compuestos moduladores de gpr52
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
CO2022000084A2 (es) Compuestos para tratar enfermedad respiratoria
CO2023015732A2 (es) Moduladores de trex1
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
MX2022004155A (es) Compuestos antagonistas del receptor 4 de prostaglandina e2 (ep4).